Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients. Alping P, Askling J, Burman J, Fink K, et al. Ann Neurol 2020 Feb 13. doi: 10.1002/ana.25701.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Alping P, Askling J, Burman J, Fink K, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients. Ann Neurol 2020 Feb 13. doi: 10.1002/ana.25701.
PMID: 32056253